Compound Radix Sophorae Flavescentis exerts antitumor effects by inhibiting the proliferation and inducing the apoptosis of esophageal carcinoma TE-8 cells

XIAOYU YANG¹, WEIMEI CAI², QINGHUI YANG², ZHIHONG LU², JINSONG LI² and JIAN YU²

¹Department of Pathology, Xinxiang Medical University; ²The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, P.R. China

Received June 18, 2015; Accepted July 22, 2015

DOI: 10.3892/ol.2015.3607

Abstract. The aim of this study was to examine the effects of compound Radix Sophorae Flavescentis on the proliferation of esophageal carcinoma TE-8 cells and to elucidate the mechanisms involved. For this purpose, we incubated TE-8 cells in medium containing various concentrations (0, 0.0125, 0.025, 0.05, 0.1, 0.2, 0.4 and 0.8 mg/ml) of the compound Radix Sophorae Flavescentis injection and its effects on the proliferation of TE-8 cells were examined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. In addition, we observed the morphological changes and measured the expression levels of apoptosis-related genes (caspase-3, Bcl-2 and Bax) in the cells treated with different doses of the compound (low-dose group, 0.05 mg/ml; medium-dose group, 0.2 mg/ml; and high-dose group, 0.8 ng/ml) by reverse transcription-quantitative PCR (RT-qPCR). The apoptotic index of the cancer cells treated with different doses of the compound was determined by TUNEL assay. Our results revealed that compared with the control group (untreated cells), the proliferation of the cancer cells treated with the compound was significantly inhibited (P≤0.05); the inhibition of the proliferation of the cancer cells occured in a dose-dependent manner. Compared with the control group, the apoptotic rate of the cells in the low-dose, medium-dose and high-dose groups increased significantly (P<0.05) in a dose-dependent manner. In addition, compared with the control group, the mRNA expression of caspase-3 and Bax increased significantly in the cells treated with the compound. However, the mRNA expression of Bcl-2 markedly decreased (P<0.05). With the gradual increase

Correspondence to: Dr Xiaoyu Yang, Department of Pathology, Xinxiang Medical University, 96 Xinfei Street, Weihui, Xinxiang, Henan 453003, P.R. China

E-mail: sunny8441_cn@sina.com

Key words: compound Radix Sophorae Flavescentis, esophageal carcinoma, apoptosis

in the drug concentration, the mRNA expression levels of caspase-3, Bcl-2 and Bax in the cancer cells were altered in a dose-dependent manner. In conclusion, our data demonstrate that compound Radix Sophorae Flavescentis injection significantly enhances the expression of pro-apoptotic genes in esophageal carcinoma TE-8 cells by increasing apoptosis and inhibiting cell proliferation. Thus, this study provides a theoretical basis for the clinical treatment of esophageal carcinoma.

Introduction

Esophageal carcinoma is one of the most common types of malignant tumors in China (1). Due to the lack of specificity of symptoms, early-stage esophageal carcinoma is difficult to detect and some patients have already entered into the advanced stages of the disease at the time of diagnosis. Chemoradiotherapy is currently the main treatment strategy (2-5) for patients with advanced-stage esophageal carcinoma. However, the adverse effects associated with chemoradiotherapy undermine the effectiveness of treatment and the quality of life of patients.

In recent years, the continuous development and study of traditional Chinese medicine herbal treatments has obtained fruitful results. The main components of compound Radix Sophorae Flavescentis injection are Radix Sophorae Flavescentis and Heterosmilacis Japonicae extract, which can clear away heat, promote diuresis, cool blood, expel miasma, remove stasis and relieve pain (6). It has been demonstrated that CKI suppresses tumor cell growth by inducing apoptosis (7) and inhibits the migration, invasion and adhesion capacity of tumor cells by downregulating the protein expression of CD44v6 (8). Few studies to date have focused on the efficacy of Kushen alkaloids using animal models and performing clinical trials before 1992, when Kushen alkaloids were first approved. Studies have proven that the compound Radix Sophorae Flavescentis may be used to improve the efficacy of chemoradiotherapy and may also improve the quality of life of patients (6,9). Clinical studies have reported that Kushen alkaloids are efficacious in the treatment of various types of solid tumors (including tumors of the lung, liver and gastrointestinal tract). The treatment responses were comparable to, or better than, those of chemotherapy drug-treated patients (10). Kushen alkaloids demonstrate a good safety profile in cancer patients, such as reduced toxicity in bone marrow when used in combination with chemotherapeutic agents (11). Long-term survival data for Kushen alkaloids-treated cancer patients remain to be demonstrated with well-controlled clinical studies and large patient cohorts. However, studies on the mechanisms of action of this compound are limited. Thus, in this study, we analyzed the anti-neoplastic effects of compound Radix Sophorae Flavescentis, as well as its mechanisms of action in *in vitro* (using esophageal carcinoma TE-8 cells), with the aim of providing a theoretical basis for the clinical treatment of esophageal carcinoma.

Materials and methods

Experimental materials

Cell culture. Human esophageal squamous cell carcinoma TE-8 cells were provided by the Laboratory of Reverse Transcriptase Molecular Biology, Xinxiang Medical College, Xinxiang, China. The cells were cultured in RPMI-1640 medium supplemented with 100 U/ml penicillin, 100 μ g/ml streptomycin and 10% (V/V) fetal bovine serum (FBS) in an incubator at 37°C with 5% CO₂. The medium was changed every 24 h and the cells were passaged once in every 48 h.

Primary reagents: the compound Radix Sophorae Flavescentis was provided by Shanxi Zhendong Pharmaceutical Co., Ltd., Changzhi, China; 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was obtained from Jingke Biotechnology Co., Ltd., Beijing, China; the apoptosis assay kit was from the Beyotime Institute of Biotechnology, Haimen, China; terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) reagent was purchased from Roche Diagnostics, Mannheim, Germany; the reverse transcription kit was obtained from Nanjing Vazyme Biotech Co., Ltd. (Nanjing, China); SYBR-Green universal qPCR Master Mix was from Roche Diagnostics; the real-time PCR system was purchased from Bio-Rad (Hercules, CA, USA); and the inverted fluorescence microscope was obtained from Leica Microsystems (Mannheim, Germany).

Treatment groups. Esophageal carcinoma TE-8 cells were inoculated in 96-well plates at a density of 5x10⁴ cells/ml, and kept in an incubator at 37°C with 5% CO₂ for overnight culture. The following day, the adherent cells (60-70% adherence) were placed in RPMI-1640 medium supplemented with 0.2% FBS, and the supernatant was extracted after 24 h. The compound Radix Sophorae Flavescentis injection was then added to the medium at various concentrations (final concentrations: 0, 0.0125, 0.025, 0.05, 0.1, 0.2, 0.4 and 0.8 mg/ml) with a total of 8 gradients, followed by culture for 24 h. There were 4 different treatment groups: the control group (untreated cells), the lowdose group (0.05 mg/ml of the compound), the medium-dose group (0.2 mg/ml of the compound) and the high-dose group (0.8 ng/ml) of the compound. Cell proliferation was then examined by MTT assay. The plate was removed, abd 20 μ l MTT solution (5 mg/ml) were added to each well. The cells were then incubated at 37°C for 4 h. The culture medium was then removed, and the cells were washed with PBS, followed by the addition of DMSO. The mixture was then vortexted for 10 min, and the light absorption (OD value) in each well was measured at 492 nm and the readings were recorded. The experiment was repeated 3 times, and the mean measurements were calculated from sextuplicate samples. The cell growth inhibition rate (%) was calculated as 1 - (mean OD value in treatment group/OD value in control group) x100.

Reverse transcription-quantitative PCR (RT-qPCR) for the determination of the expression of apoptosis-related genes. The cells treated with various doses of the compound (low dose, medium dose and high dose (0.05, 0.2 and 0.8 mg/ml, respectively) were treated with 1 ml of TRIzol reagent (Beyotime Institute of Biotechnology) and placed in a 1.5 ml centrifuge tube. Subsequently, 200 μ l chloroform was added, and the tube was shaken vigorously (for mixing) and then place on ice for 15 min to layer, followed by centrifugation at 12,000 rpm/min for 15 min. When the liquid appeared as the layer, the supernatant was placed in 500 µl isopropanol, on ice, after mixing until the RNA precipitated out and was then centrifuged at 12,000 rpm/min for 10 min. The precipitate was washed with 75% pre cooling anhydrous ethanol twice; it was then dissolve in double-distilled water without RNA enzyme. Following the detection of the concentration of sample, the RNA was reverse transcribed into cDNA using the reverse transcription kit. The primers used for PCR were as follows: caspase-3 forward, 5'-GGTATTGAGACAGACAGTGG-3' and reverse, 5'-CATG GGATCTGTTTCTTTGC-3'; β-actin forward, 5'-GCGGGAA ATCGTGCGTGAC-3' and reverse, CGTCATACTCCT GCTTGCTG-3'; Bax forward, 5'-TCCACCAAGAAGCT GAGCGAG-3' and reverse, 5'-GTCCAGCCCATGATG GTTCT-3'; Bcl-2 forward, 5'-TTCTTTGAGTTCGGTGG GGTC-3' and reverse, 5'-TGCATATTTGTTTGGGGCAGG-3'. The reaction mixture was prepared using the following reaction system: 2X SYBR-Green universal 10 μ l qPCR Master Mix, 1 μ upstream/downstream primer (10 μmmolxl⁻¹), 1 μl cDNA and $20 \mu l$ double-distilled water. The following reaction conditions were used for PCR: initial denaturation, 95°C, 30 sec; degeneration, 95°C, 3 sec; annealing and extension, 60°C, 30 sec; building of solubility curve. Finally, the data were analyzed using LightCycler software.

Calculation of apoptotic index TUNEL assay. The TE-8 cells were digested and kept in monoplast suspension, and inoculated in a culture dish containing a glass slide with at 1x10⁵ cells/ml; the groups and treatment conditions were the same as those described above. The medium was removed after 48 h, the glass slide was removed and TUNEL assay was carried out according to the instructions provided by the manufacturer. The slide was removed, washed with PBS for 3 times, fixed in 4% paraformaldehyde for 40 min, and washed with PBS for 3x3 min. The slide was blocked at room temperature for 10 min, washed with PBS for 3x3 min, placed at 4°C for 3 min, washed with cold PBS for 2x5 min, followed by the addition of labeling mixture. It was then incubated in a dark and wet environment at 37°C for 60 min, washed with PBS for 3x5 min, followed by the addition of 50 μ l transformation solution. It was then incubated in a dark and wet environment at 37°C for 30 min, and washed with PBS for 3x5 min again. DAB was then added and the slide was observed under a microscope. The slide was restained




Figure 1. Effect of compound Radix Sophorae Flavescentis on the proliferation of esophageal carcinoma TE-8 cells. Inhibitory effect of various concentrations of Radix Sophorae Flavescentis on the proliferation of TE-8 cells.




Figure 2. Effect of compound Radix Sophorae Flavescentis on mRNA expression of apoptosis-related genes (caspase-3, Bcl-2 and Bax) in esophageal carcinoma TE-8 cells. The cells were treated with various doses of the compound (low-dose group, 0.05 mg/ml; medium-dose group, 0.2 mg/ml; and high-dose group, 0.8 ng/ml) and the mRNA expression levels were measured by RT-qPCR. *P<0.05.

with haematoxylin, dehydrated, transparentized and mounted on a microscope for observation. TUNEL-positive cells were indicated by a brown nucleus. The cells were then observed under a microscope at at 5-10 fields of vision on a high-power lens (x400 magnification) so that each field of vision included 100-200 cells. The total number of cells was approximately 500-1,000 and the proportion of cell apoptosis was calculated as the apoptotic rate.

Statistical analysis. All the data was analyzed using statistical software SPSS 17.0, and the data are expressed as the means ± SD. Comparisons among groups were made by one-way analysis of variance (ANOVA), and pairwise comparisons were made using the LSD method. The survival curve was estimated using the Kaplan-Meier method and the log-rank test. A value of P<0.05 was considered to indicate a statistically significant difference.

Results

Effect of compound Radix Sophorae Flavescentis injection on the proliferation of esophageal carcinoma TE-8 cells. As shown in Fig. 1, compared with untreated control group, cell proliferation was significantly inhibited in the cells treated with the compound in a dose-dependent manner (P<0.05).

Effect of compound Radix Sophorae Flavescentis injection on the expression of apoptosis-related genes in esophageal carcinoma TE-8 cells. After the cancer cells were treated with various concentrations of the compound Radix Sophorae Flavescentis, the mRNA expression levels of the apoptosisrelated genes, caspase-3, Bcl-2 and Bax, were measured by RT-qPCR and the results are shown in Fig. 2. Compared with the control group, the mRNA expression levels of caspase-3 and Bax significantly increased in the cells in the low-dose, mediumdose and high-dose groups, whereas the mRNA expression level of Bcl-2 markedly decreased (P<0.05). The increase in the mRNA expression of caspase-3 and Bax in the different treatment groups was as follows (in the order of lowest to highest): low-dose group<medium-dose group<high-dose group. The decrease in the mRNA expression of Bcl-2 in the different treatment groups was as follows (in the order of highest to lowest): low-dose group>medium-dose group>high-dose group.

Effect of compound Radix Sophorae Flavescentis injection on the apoptotic index in esophageal carcinoma TE-8 cells.




Figure 3. Effect of compound Radix Sophorae Flavescentis on the apoptotic index in TE-8 cells. (A and B) The cells were treated with various doses of the compound (low-dose group, 0.05 mg/ml; medium-dose group, 0.2 mg/ml; and high-dose group, 0.8 ng/ml) and the apoptotic index was calculated by TUNEL assay. *P<0.05.

The apoptotic index in the cancer cells was calculated using TUNEL asay and the results are presented in Fig. 3. The number of apoptotic the cells in the control group was low; however, following treatment with increasing doses of the compound, cell apoptosis gradually increased. The quantitative analysis of the results of cell apoptosis is shown in Fig. 3B. Compared with the control group, the apoptotic index of the cancer cells in the low-dose, medium-dose and high-dose groups increased significantly and the difference was statistically significant (P<0.05). The apoptotic index in the different gropus ranged as follows (in the order of highest to lowest): high-dose group>medium-dose group>low-dose group.

Discussion

Esophageal carcinoma is one of the most common gastrointestinal malignancies within the category of 'hiccough' and 'phrenic' in traditional Chinese medicine and its pathogenesis is 'qi, phlegm, blood stasis and heat' (12). Thus, the treatment of esophageal carcinoma should aim to clear heat, transform phlegm and soften hardness. The main components of the compound Radix Sophorae Flavescentis injection are Radix Sophorae Flavescentis and Heterosmilacis Japonicae extract, which can clear heat, promote diuresis, cool blood, expel miasma, remove stasis and relieve pain (13).

It has been demonstrated that the compound Radix Sophorae Flavescentis injection exerts antitumor effects and can alleviaate pain, bleeding, fatigue and other discomforts (14). It has also been reported that (15) that matrine can kill malignant tumor cells and promotes cancer cell apoptosis. In this study, we investigated the antitumor effects of the compound Radix Sophorae Flavescentis injection by treating esophageal carcinoma TE-8

cells with different doses of the compound and found that the compound significantly inhibited the proliferation of the cancer cells in a dose-dependent manner. Thus, the compound Radix Sophorae Flavescentis injection inhibits the proliferation of esophageal carcinoma cells.

In this study, we also measured the mRNA expression of apoptosis-related genes in esophageal carcinoma TE-8 cells and the results revealed that the mRNA expression of caspase-3 and Bax was significantly higher in the cells treated with a high dose of the compound (0.8 mg/ml) compared with the control group, whereas the mRNA expression of Bcl-2 markedly decreased in the cells treated with the compound compared with control group. Caspase-3 is a common molecule of the cell apoptosis pathway, which plays an important role in the process mediating apoptosis (16). An increase in its expression promotes apoptosis. In our study, treatment with the compound Radix Sophorae Flavescentis injection induced an increase in the expression of caspase-3, resulting in the apoptosis of the esophageal carcinoma cells. The balance of Bcl-2 and Bax also plays an important role in the process of apoptosis in cancer cells, with the increase in Bcl-2 expression indicating the inhibition of apoptosis, and the decrease in Bax expression maintaining the proliferation of cancer cells (17-19). In our study, following treatment of the cancer cells with the compound Radix Sophorae Flavescentis injection, Bcl-2 expression markedly decreased and Bax expression significantly increased, indicating an increase in apoptosis. The induction of apoptosis may be one of the mechanisms through which the compound Radix Sophorae Flavescentis injection inhibits the growth of tumors. Cancer cell apoptosis caused by compound Radix Sophorae Flavescentis injection was further verified by TUNEL assay.

In conclusion, our study demonstrated that compound Radix Sophorae Flavescentis injection significantly inhibited the proliferation of esophageal carcinoma TE-8 cells and induced apoptosis. Thus, compound Radix Sophorae Flavescentis injection may prove to be a valuable and effective therapeutic agent for the treatment of esophageal carcinoma.

References

- Dongxin L: Esophageal cancer molecular epidemiology research in China. Zhonghua Liu Xing Bing Xue Za Zhi 24: 939-943, 2003 (In Chinese).
- Chen J, Zhu J, Pan J, Zhu K, Zheng X, Chen M, Wang J and Liao Z: Postoperative radiotherapy improved survival of poor prognostic squamous cell carcinoma esophagus. Ann Thorac Surg 90: 435-442, 2010.
- 3. Mariette C, Piessen G and Triboulet JP: Therapeutic strategies in oesophageal carcinoma: Role of surgery and other modalities. Lancet Oncol 8: 545-553, 2007.
- 4. Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, Takiyama W, Watanabe H, Isono K, Aoyama N, et al; Japan Clinical Oncology Group: Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: A Japan Clinical Oncology Group Study JCOG9204. J Clin Oncol 21: 4592-4596, 2003.
- Rice TW, Adelstein DJ, Chidel MA, Rybicki LA, DeCamp MM, Murthy SC and Blackstone EH: Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinoma. J Thorac Cardiovasc Surg 126: 1590-1596, 2003.
- Qi L, Zhang J and Zhang Z: Determination of four alkaloids in compound Kushen Injection by high performance liquid chromatography with ionic liquid as mobile phase additive. Se Pu 31: 249-253, 2013 (In Chinese).
- 7. Dai ZJ, Gao J, Wang XJ, Ji ZZ, Wu WY, Liu XX, Kang HF, Guan HT and Ren HT: Apoptotic mechanism of gastric carcinoma cells induced by matrine injection. Zhonghua Wei Chang Wai Ke Za Zhi 11: 261-265, 2008 (In Chinese).
- 8. Dai ZJ, Gao J, Wu WY, Wang XJ, Li ZF, Kang HF, Liu XX and Ma XB. Effect of matrine injections on invasion and metastasis of gastric carcinoma SGC-7901 cells in vitro. Zhong Yao Cai 30: 815-819, 2007 (In Chinese).

- 9. Sun Q, Ma W, Gao Y, Zheng W, Zhang B and Peng Y: Meta-analysis: therapeutic effect of transcatheter arterial chemoembolization combined with compound kushen injection in hepatocellular carcinoma. Afr J Tradit Complement Altern Med 9: 178-188, 2012.
- Zhu JL and Chen JZ: Short-term observation on the efficacy of matrine injection in treating 79 cases of late stage cancers. Shandong Med J 43: article 40, 2003.
- 11. Willert K, Brown JD, Danenberg E, Duncan AW, Weissman IL, Reya T, Yates JR III and Nusse R: Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 423: 448-452, 2003.
- 12. Zhou H and Huang GH: Cognition and treatment research of traditional Chinese medicine for esophagus cancer. Liaoning Zhong Yi Yao Da Xue Xue Bao 2: 212-215, 2012 (In Chinese).
- 13. Hai LN, Zhang ZW and Wang JH: Effects of compound Kushen injection on alalgesis, hemostasis and anti-stress in mice. Zhongguo Shi Yan Fang Ji Xue Za Zhi 50: 199-202, 2012 (In Chinese).
- Ma Y, Zhang QW, Wang ZM and Gao HM: Advance in study on compound Kushen injection. Zhongguo Shi Yan Fang Ji Xue Za Zhi 18: 23-24, 2012.
- 15. Tuo XL and Bai M: Expression and significance of human mismatch repair gene (Smsh2) and proliferating cell nuclear antigen (PCNA) in lung cancer. China J Modem Med 15: 691, 2005.
- 16. Simpson KL, Cawthorne C, Zhou C, Hodgkinson CL, Walker MJ, Trapani F, Kadirvel M, Brown G, Dawson MJ, MacFarlane M, et al: A caspase-3 'death-switch' in colorectal cancer cells for induced and synchronous tumor apoptosis in vitro and in vivo facilitates the development of minimally invasive cell death biomarkers. Cell Death Dis 4: e613, 2013.
- 17. Raisova M, Hossini AM, Eberle J, Riebeling C, Wieder T, Sturm I, Daniel PT, Orfanos CE and Geilen CC: The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis. J Invest Dermatol 117: 333-340, 2001.
- 18. Salakou S, Kardamakis D, Tsamandas AC, Zolota V, Apostolakis E, Tzelepi V, Papathanasopoulos P, Bonikos DS, Papapetropoulos T, Petsas T, *et al*: Increased Bax/Bcl-2 ratio up-regulates caspase-3 and increases apoptosis in the thymus of patients with myasthenia gravis. In Vivo 21: 123-132, 2007.
- Adams JM and Cory S: Bcl-2-regulated apoptosis: Mechanism and therapeutic potential. Curr Opin Immunol 19: 488-496, 2007.